GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dimed SA Distribuidora de Medicamentos (BSP:PNVL3) » Definitions » Return-on-Tangible-Equity

Dimed Distribuidora de Medicamentos (BSP:PNVL3) Return-on-Tangible-Equity : 8.91% (As of Mar. 2025)


View and export this data going back to 1995. Start your Free Trial

What is Dimed Distribuidora de Medicamentos Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Dimed Distribuidora de Medicamentos's annualized net income for the quarter that ended in Mar. 2025 was R$102 Mil. Dimed Distribuidora de Medicamentos's average shareholder tangible equity for the quarter that ended in Mar. 2025 was R$1,143 Mil. Therefore, Dimed Distribuidora de Medicamentos's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was 8.91%.

The historical rank and industry rank for Dimed Distribuidora de Medicamentos's Return-on-Tangible-Equity or its related term are showing as below:

BSP:PNVL3' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.71   Med: 11.86   Max: 17.75
Current: 8.73

During the past 13 years, Dimed Distribuidora de Medicamentos's highest Return-on-Tangible-Equity was 17.75%. The lowest was 7.71%. And the median was 11.86%.

BSP:PNVL3's Return-on-Tangible-Equity is ranked better than
56.24% of 905 companies
in the Drug Manufacturers industry
Industry Median: 6.7 vs BSP:PNVL3: 8.73

Dimed Distribuidora de Medicamentos Return-on-Tangible-Equity Historical Data

The historical data trend for Dimed Distribuidora de Medicamentos's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dimed Distribuidora de Medicamentos Return-on-Tangible-Equity Chart

Dimed Distribuidora de Medicamentos Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.71 8.14 8.56 8.76 9.47

Dimed Distribuidora de Medicamentos Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.20 1.87 13.13 11.06 8.91

Competitive Comparison of Dimed Distribuidora de Medicamentos's Return-on-Tangible-Equity

For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dimed Distribuidora de Medicamentos's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Dimed Distribuidora de Medicamentos's Return-on-Tangible-Equity falls into.


;
;

Dimed Distribuidora de Medicamentos Return-on-Tangible-Equity Calculation

Dimed Distribuidora de Medicamentos's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=105.509/( (1090.099+1138.043 )/ 2 )
=105.509/1114.071
=9.47 %

Dimed Distribuidora de Medicamentos's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=101.864/( (1138.043+1147.33)/ 2 )
=101.864/1142.6865
=8.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Dimed Distribuidora de Medicamentos  (BSP:PNVL3) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Dimed Distribuidora de Medicamentos Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Dimed Distribuidora de Medicamentos's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Dimed Distribuidora de Medicamentos Business Description

Traded in Other Exchanges
N/A
Address
Avenida Industrial Belgraf, 865, Eldorado do Sul, RS, BRA, 92990-000
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. Its segments are divided into Retail, Wholesale and Corporate. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. The Wholesale segment is the distributor of drugs in Brazil. The Corporate segment includes Wholesale and Retail, as well as the subsidiary Lifar. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.

Dimed Distribuidora de Medicamentos Headlines

No Headlines